OPRK1 and cancer: Peripherally restricted KOR agonists may serve as adjuncts to conventional analgesics in inflammatory and cancer pain, whereas G protein-biased ligands might be preferred for chronic neuropathic pain to enhance efficacy and minimize CNS adverse effects.